An immune, stroma, and epithelial–mesenchymal transition‐related signature for predicting recurrence and chemotherapy benefit in stage II–III colorectal cancer
التفاصيل البيبلوغرافية
العنوان:
An immune, stroma, and epithelial–mesenchymal transition‐related signature for predicting recurrence and chemotherapy benefit in stage II–III colorectal cancer
Abstract Background Debates exist on the treatment decision of the stage II/III colorectal cancer (CRC) due to the insufficiency of the current TNM stage‐based risk stratification system. Epithelial–mesenchymal transition (EMT) and tumor microenvironment (TME) have both been linked to CRC progression in recent studies. We propose to improve the prognosis prediction of CRC by integrating TME and EMT. Methods In total, 2382 CRC patients from seven datasets and one in‐house cohort were collected, and 1640 stage II/III CRC patients with complete survival information and gene expression profiles were retained and divided into a training cohort and three independent validation cohorts. Integrated analysis of 398 immune, stroma, and epithelial‐mesenchymal transition (ISE)‐related genes identified an ISE signature independently associated with the recurrence of CRC. The underlying biological mechanism of the ISE signature and its influence on adjuvant chemotherapy was further explored. Results We constructed a 26‐gene signature which was significantly associated with poor outcome in Training cohort (p
Full Text Finder